These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 38293914)
1. Comparison of Effectiveness Among Different Sodium-Glucose Cotransoporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials. Kani R; Watanabe A; Miyamoto Y; Ejiri K; Iwagami M; Takagi H; Slipczuk L; Tsugawa Y; Aikawa T; Kuno T J Am Heart Assoc; 2024 Feb; 13(3):e031805. PubMed ID: 38293914 [TBL] [Abstract][Full Text] [Related]
2. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials. Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304 [TBL] [Abstract][Full Text] [Related]
3. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Qiu M; Ding LL; Zhang M; Zhou HR Diab Vasc Dis Res; 2021; 18(2):14791641211011016. PubMed ID: 33887983 [TBL] [Abstract][Full Text] [Related]
4. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Wanner C; Iliev H; Duarte N; Schueler E; Soares AR; Thanam V; Pfarr E Adv Ther; 2024 Jul; 41(7):2826-2844. PubMed ID: 38771475 [TBL] [Abstract][Full Text] [Related]
5. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. ; Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458 [TBL] [Abstract][Full Text] [Related]
6. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550 [TBL] [Abstract][Full Text] [Related]
7. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. Yang S; Zhao L; Mi Y; He W Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807 [TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials. Duan XY; Liu SY; Yin DG Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. Tian L; Ai S; Zheng H; Yang H; Zhou M; Tang J; Liu W; Zhao W; Wang Y Front Pharmacol; 2022; 13():986186. PubMed ID: 36506550 [TBL] [Abstract][Full Text] [Related]
10. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury. Chu C; Lu YP; Yin L; Hocher B Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483 [TBL] [Abstract][Full Text] [Related]
11. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Starr JA; Pinner NA Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700 [TBL] [Abstract][Full Text] [Related]
13. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials. Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484 [TBL] [Abstract][Full Text] [Related]
14. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900 [TBL] [Abstract][Full Text] [Related]
15. Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. Hamid AK; Tayem AA; Al-Aish ST; Al Sakini AS; Hadi DD; Al-Aish RT Ther Adv Cardiovasc Dis; 2024; 18():17539447241289067. PubMed ID: 39400108 [TBL] [Abstract][Full Text] [Related]
16. Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods. Chen HB; Yang YL; Meng RS; Liu XW ESC Heart Fail; 2023 Apr; 10(2):1231-1241. PubMed ID: 36702979 [TBL] [Abstract][Full Text] [Related]
17. Can we go beyond surrogates? Drexler A J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750 [TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355 [TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Chen HB; Yang YL; Yu TH; Li YH Eur J Pharmacol; 2022 Dec; 936():175354. PubMed ID: 36306924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]